The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Drug—drug interaction through molecular structure similarity analysis
Open accessAbstract
BACKGROUND: Drug-drug interactions (DDIs) are responsible for many serious adverse events; their detection is crucial for patient safety but is very challenging. Currently, the US Food and Drug Administration and pharmaceutical companies are showing great interest in the development of improved tools for identifying DDIs. METHODS: We present a new methodology applicable on a large scale that identifies novel DDIs based on molecular structural similarity to drugs involved in established DDIs. The underlying assumption is that if drug A and drug B interact to produce a specific biological effect, then drugs similar to drug A (or drug B) are likely to interact with drug B (or drug A) to produce the same effect. DrugBank was used as a resource for collecting 9454 established DDIs. The structural similarity of all pairs of drugs in DrugBank was computed to identify DDI candidates. RESULTS: The methodology was evaluated using as a gold standard the interactions retrieved from the initial DrugBank database. Results demonstrated an overall sensitivity of 0.68, specificity of 0.96, and precision of 0.26. Additionally, the methodology was also evaluated in an independent test using the Micromedex/Drugdex database. CONCLUSION: The proposed methodology is simple, efficient, allows the investigation of large numbers of drugs, and helps highlight the etiology of DDI. A database of 58 403 predicted DDIs with structural evidence is provided as an open resource for investigators seeking to analyze DDIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
Incidence of Adverse Drug Events and Potential Adverse Drug Events: Implications for Prevention
Bates, D. W. (1995) · JAMA · doi:10.1001/jama.1995.03530010043033 · Cited by 2,127
Reoptimization of MDL Keys for Use in Drug Discovery
Durant, J. L., Leland, B. A., Henry, D. R., & Nourse, J. G. (2002) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci010132r · Cited by 1,862
Bates, D. W. (1997) · JAMA · doi:10.1001/jama.277.4.307 · Cited by 1,674
Vilar, S., Cozza, G., & Moro, S. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608786786624 · Cited by 1,191
Self-citationClassen, D. C. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540280039031 · Cited by 1,134
The Costs of Adverse Drug Events in Hospitalized Patients
Bates, D. W. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540280045032 · Cited by 1,068
Do Structurally Similar Molecules Have Similar Biological Activity?
Martin, Y. C., Kofron, J. L., & Traphagen, L. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020155c · Cited by 806
Bjornsson, T. D., Callaghan, J. T., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., Kao, J., King, S. P., Miwa, G., Ni, L., et al. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.815 · Cited by 792
Cerivastatin and Reports of Fatal Rhabdomyolysis
Staffa, J. A., Chang, J., & Green, L. (2002) · New England Journal of Medicine · doi:10.1056/nejm200202143460721 · Cited by 626
Cullen, D. J., Sweitzer, B. J., Bates, D. W., Burdick, E., Edmondson, A., & Leape, L. L. (1997) · Critical Care Medicine · doi:10.1097/00003246-199708000-00014 · Cited by 611
The Incident Reporting System Does Not Detect Adverse Drug Events: A Problem for Quality Improvement
Cullen, D. J., Bates, D. W., Small, S. D., Cooper, J. B., Nemeskal, A. R., & Leape, L. L. (1995) · The Joint Commission Journal on Quality Improvement · doi:10.1016/s1070-3241(16)30180-8 · Cited by 600
Adverse drug events in hospitalized patients
van den Bemt, P. M. L. A., Egberts, A. C. G., Lenderink, A. W., Verzijl, J. M., Simons, K. A., van der Pol, W. S. C. J. M., & Leufkens, H. G. M. (1999) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050611 · Cited by 460
Wang, X., Hripcsak, G., Markatou, M., & Friedman, C. (2009) · Journal of the American Medical Informatics Association · doi:10.1197/jamia.m3028 · Cited by 288
Self-citationSchneeweiss, S., Hasford, J., Göttler, M., Hoffmann, A., Riethling, A.-K., & Avorn, J. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-002-0467-0 · Cited by 274
Predicting Drug–Drug Interactions: An FDA Perspective
Zhang, L., Zhang, Y., Zhao, P., & Huang, S.-M. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9106-3 · Cited by 267
Adverse drug reactions as a cause for admissions to a department of internal medicine
Mjörndal, T., Boman, M. D., Hägg, S., Bäckström, M., Wiholm, B., Wahlin, A., & Dahlqvist, R. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.667 · Cited by 213
Tatonetti, N. P., Fernald, G. H., & Altman, R. B. (2012) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000214 · Cited by 203
Tatonetti, N. P., Denny, J. C., Murphy, S. N., Fernald, G. H., Krishnan, G., Castro, V, Yue, P., Tsau, P. S., Kohane, I., Roden, D. M., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.83 · Cited by 201
Mining multi-item drug adverse effect associations in spontaneous reporting systems
Harpaz, R., Chase, H. S., & Friedman, C. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-s9-s7 · Cited by 171
Self-citationQuantifying the Relationships among Drug Classes
Hert, J., Keiser, M. J., Irwin, J. J., Oprea, T. I., & Shoichet, B. K. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci8000259 · Cited by 169
Outcomes of Emergency Department Patients Presenting With Adverse Drug Events
Hohl, C. M., Nosyk, B., Kuramoto, L., Zed, P. J., Brubacher, J. R., Abu‐Laban, R. B., Sheps, S. B., & Sobolev, B. G. (2011) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2011.01.003 · Cited by 114
Vilar, S., Santana, L., & Uriarte, E. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050932j · Cited by 83
Self-citationA Virtual Screen for Diverse Ligands: Discovery of Selective G Protein-Coupled Receptor Antagonists
Engel, S., Skoumbourdis, A. P., Childress, J., Neumann, S., Deschamps, J. R., Thomas, C. J., Colson, A., Costanzi, S., & Gershengorn, M. C. (2008) · Journal of the American Chemical Society · doi:10.1021/ja077620l · Cited by 75
Comparison of Molecular Fingerprint Methods on the Basis of Biological Profile Data
Steffen, A., Kogej, T., Tyrchan, C., & Engkvist, O. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci800326z · Cited by 72
Drug Interactions of Clinical Importance An Updated Guide
Quinn, D. I., & Day, R. O. (1995) · Drug Safety · doi:10.2165/00002018-199512060-00005 · Cited by 65
Vilar, S., Harpaz, R., Chase, H. S., Costanzi, S., Rabadán, R., & Friedman, C. (2011) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000417 · Cited by 64
Self-citationRisk Management of Simvastatin or Atorvastatin Interactions with CYP3A4 Inhibitors
Molden, E., Skovlund, E., & Braathen, P. (2008) · Drug Safety · doi:10.2165/00002018-200831070-00004 · Cited by 50
Vilar, S., Karpiak, J. D., & Costanzi, S. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21346 · Cited by 46
Self-citationSimulation models for drug disposition and drug interactions
Dickins, M., & Waterbeemd, H. V. D. (2004) · Drug Discovery Today BIOSILICO · doi:10.1016/s1741-8364(04)02388-1 · Cited by 42
Costanzi, S., Vilar, S., Micozzi, D., Carpi, F. M., Ferino, G., Vita, A., & Vincenzetti, S. (2011) · ChemMedChem · doi:10.1002/cmdc.201100139 · Cited by 15
Self-citation
Cited by
Modeling polypharmacy side effects with graph convolutional networks
Zitnik, M., Agrawal, M., & Leskovec, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty294 · Cited by 1,501
Zitnik, M., Nguyen, F., Wang, B., Leskovec, J., Goldenberg, A., & Hoffman, M. M. (2019) · Information Fusion · doi:10.1016/j.inffus.2018.09.012 · Cited by 675
Deep learning improves prediction of drug–drug and drug–food interactions
Ryu, J. Y., Kim, H. U., & Lee, S. Y. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803294115 · Cited by 655
Computational methods in drug discovery
Leelananda, S. P., & Lindert, S. (2016) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.12.267 · Cited by 639
A multimodal deep learning framework for predicting drug–drug interaction events
Deng, Y., Xu, X., Qiu, Y., Xia, J., Zhang, W., & Liu, S. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa501 · Cited by 453
Metadata
- Authors
- Vilar, S., Harpaz, R., Uriarte, E., Santana, L., Rabadan, R., & Friedman, C.
- Venue
- Journal of the American Medical Informatics Association
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-11
- Volume
- 19
- Issue
- 6
- Pages
- 1066-1074
- ISSN
- 1067-5027 (ISSN-L)
- 1527-974X
- OpenAlex
- W2106417713
- Cited by
- 288
- References
- 31
- FWCI
- 8.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.